<DOC>
	<DOCNO>NCT01179295</DOCNO>
	<brief_summary>This uncontrolled , open-label , non-randomized phase I / pharmacokinetic study oral BAY86-9766 investigate safety , tolerability , pharmacokinetics , efficacy profile Japanese patient advance solid tumor</brief_summary>
	<brief_title>Japanese BAY86-9766 Monotherapy Phase I Study</brief_title>
	<detailed_description />
	<criteria>Japanese patient , least 18 year age first screen examination/ visit , advanced refractory solid tumor amenable standard therapy . Histological cytological documentation nonhematologic , malignant solid tumor , exclude primary brain spinal tumor , current involvement central nervous system ( CNS ) At least one measurable lesion evaluable disease accord response evaluation criterion solid tumor ( RECIST ) version 1.1 Eastern cooperative oncology group performance status ( ECOGPS ) 0 1 Life expectancy least 12 week Use anticancer therapy include chemotherapy , investigational agent device immunotherapy within 4 week first dose study medication Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management Known human immunodeficiency virus ( HIV ) infection chronic active hepatitis B C Inadequate bone marrow , liver renal function Inability swallow oral medication condition could affect absorption orally administer drug Concomitant treatment cytochrome P450 isoenzymes CYP3A4 inhibitors/inducers , CYP2C19 inhibitors/ inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>MEK inhibitor</keyword>
	<keyword>BAY86-9766</keyword>
	<keyword>RDEA 119</keyword>
	<keyword>Solid tumor</keyword>
</DOC>